Pharmaceuticals News

– Afimetoran, an investigational oral, once-daily, equipotent TLR7/8 inhibitor, targets a central driver of lupus biology with the potential to address both cutaneous and systemic disease – – Global,...

BEDFORD, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today...

NASHVILLE, Tenn., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the launch of HarrowRx, a...

Consolidation of Foss Cultivation and Pre-roll Production into Optimized Masson and Cayuga Facilities Expected to Generate Approximately US$10 Million in Annualized Cost Savings Higher Cultivation...

Lexeo Therapeutics to Present Multiple Oral and Poster Presentations at Key Scientific Conferences in November

REYKJAVIK, ICELAND (November 2, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients...

Alvotech (NASDAQ: ALVO, ALVO SDB) kemur fram á fjórum alþjóðlegum fjárfestaráðstefnum í nóvember, í Bretlandi, Noregi og Svíþjóð. Alþjóðleg líftækniráðstefna UBS í London – samtal við greinanda...

REYKJAVIK, Iceland, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for...

ET-900 targets a potential new indication for mecasermin, the active ingredient in Eton’s INCRELEX®Eton has licensed patent rights from Baylor College of Medicine covering the use of insulin-like...

Björn Tackenberg, M.D. Ph.D. FEAN FAAN, Professor of Neurology, will lead Oculis’ global integrated scientific strategy supporting the advancement of Privosegtor and its expansion into new therapeutic...